Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

VivoSim Labs, INC.

  • SAN DIEGO, California
  • Public · NASDAQ: VIVS
  • 9 employees
$3.5MMarket cap
$144.0KRevenue · FY2025
-$2.5MNet income
9Employees
VIVSNASDAQ
2011IPO

About VivoSim Labs, INC.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$144.0K
Net income
-$2.5M
Total assets
$14.7M
Market cap
$3.5M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: VIVS

15-minute delayed · data by Polygon.io

Market cap
$3.5M
Open
Day range
Prev close
Volume
IPO date
Aug 16, 2011

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review VivoSim Labs, INC..

Write a review
Explore

Similar companies

Browse all →